共 25 条
Application of Photodynamic Therapy with 5-Aminolevulinic Acid to Extracorporeal Photopheresis in the Treatment of Cutaneous T-Cell Lymphoma: A First-in-Human Phase I/II Study
被引:1
作者:
Christensen, Eidi
[1
,2
,3
]
Foss, Olav Andreas
[4
]
Holien, Toril
[5
,6
]
Juzenas, Petras
[3
]
Peng, Qian
[3
,7
]
机构:
[1] Trondheim Reg & Univ Hosp, St Olavs Hosp, Dept Dermatol, N-7030 Trondheim, Norway
[2] Norwegian Univ Sci & Technol NTNU, Dept Clin & Mol Med, N-7030 Trondheim, Norway
[3] Oslo Univ Hosp, Dept Pathol, Norwegian Radium Hosp, N-0310 Oslo, Norway
[4] Trondheim Reg & Univ Hosp, St Olavs Hosp, Dept Orthopaed Surg, Clin Orthopaed Rheumatol & Dermatol, N-7030 Trondheim, Norway
[5] Norwegian Univ Sci & Technol NTNU, Dept Biomed Lab Sci, N-7491 Trondheim, Norway
[6] Trondheim Reg & Univ Hosp, St Olavs Hosp, Dept Immunol & Transfus Med, N-7030 Trondheim, Norway
[7] Fudan Univ, Sch Informat Sci & Technol, Dept Opt Sci & Engn, Shanghai 200433, Peoples R China
关键词:
5-aminolevulinic acid;
ALA-based photodynamic therapy;
phototherapy;
extracorporeal photopheresis;
cutaneous T-cell lymphoma;
CLINICAL-RESEARCH;
SKIN-DISEASE;
D O I:
10.3390/pharmaceutics16060815
中图分类号:
R9 [药学];
学科分类号:
1007 ;
摘要:
Extracorporeal photopheresis (ECP) is a therapeutic modality used for T-cell-mediated disorders. This approach involves exposing isolated white blood cells to photoactivatable 8-methoxypsoralen (8-MOP) and UVA light, aiming to induce apoptosis in T-cells and thereby modulate immune responses. However, conventional 8-MOP-ECP lacks cell selectivity, killing both healthy and diseased cells, and has shown limited treatment efficacy. An alternative approach under investigation involves the use of 5-aminolevulinic acid (ALA) in conjunction with light, referred to as ALA-based photodynamic therapy. Our previous ex vivo studies suggest that ALA-ECP exhibits greater selectivity and efficiency in killing T-cells derived from patients with T-cell-mediated disorders compared to those treated with 8-MOP-ECP. We have conducted a clinical phase I-(II) study evaluating ALA-ECP safety and tolerability in cutaneous T-cell lymphoma (CTCL). Here, 20 ALA-ECP treatments were administered to one CTCL patient, revealing no significant changes in vital signs. Two adverse events were reported; both evaluated by the Internal Safety Review Committee as non-serious. In addition, five conceivable events with mainly mild symptoms took place. During the study period, a 53% reduction in skin involvement and a 50% reduction in pruritus was observed. In conclusion, the results indicate that ALA-ECP treatment is safe and well tolerated.
引用
收藏
页数:12
相关论文